Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
NCT ID NCT04680611
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study looks at how mepolizumab (Nucala), a treatment for severe eosinophilic asthma, impacts emotions and mental well-being in patients and their partners. Researchers will track changes in feelings like anxiety, depression, and stress using questionnaires and interviews. The goal is to understand the broader psychological effects of this therapy beyond just lung function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mepolizumab (Nucala)
- What this could lead to
- If successful, this could reveal how a biologic treatment for severe asthma improves emotional health and quality of life for patients and their partners.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all asthma patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
120 people
The number who actually took part.
- Started
-
Sep 2021
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with severe eosinophilic asthma on mepolizumab treatment (Phase 1) Patients with sereve eosinophilic asthma who are to start mepolizumab treatment and their partners ( Phase 2 and 3)
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Phase 1: * Age 18 or over * Having a diagnosis of severe eosinophilic asthma * Currently on mepolizumab (Nucala®) treatment * At least basic command of English * Giving written informed consent Phase 2 Patient eligibility Inclusion criteria * Age 18 or over * Having a diagnosis of severe eosinophilic asthma * Scheduled to start mepolizumab (Nucala®) treatment * At least basic command of English (for sub-study: conversational level of English that does not require a translator) * Giving written informed consent * Co-habiting with an intimate partner who is willing to participate in the study Exclusion criteria * Participated in Phase 1 * Currently on mepolizumab (Nucala®) treatment * Major psychiatric disorder currently under treatment * History of any major psychiatric disorder in the last 5 years, excluding depressive and anxiety disorders that can be included if treatment or change of treatment (including change in dose of medication) has not started within the last 6 months * Any diagnosed severe comorbid chronic condition that, in the opinion of the patient's asthma physician, might impact on the patient's or partner's affective state (e.g. cancer, diabetes, heart failure, chronic liver disease, chronic kidney disease, autoimmune or neuro-degenerative disease). * Partners only: diagnosis of severe eosinophilic asthma * Death of spouse, main informal carer or first-degree family member within the last 3 months * Current oral corticosteroid maintenance treatment Partner eligibility Inclusion criteria * Age 18 or over * At least basic command of English (for sub-study: conversational level of English that does not require a translator) * Giving written informed consent * Partners: Co-habiting with an intimate partner who has severe eosinophilic asthma and is willing to participate in the study Exclusion criteria * Participated in Phase 1 * Major psychiatric disorder currently under treatment * Participant self-reported history of any major psychiatric disorder in the last 5 years, excluding depressive and anxiety disorders that can be included if treatment or change of treatment (including change in dose of medication) has not started within the last 6 months. * Participant self-reported any diagnosed severe comorbid chronic condition that, in the opinion of the patient's asthma physician, might impact on the patient's or partner's affective state (e.g. cancer, diabetes, heart failure, chronic liver disease, chronic kidney disease, autoimmune or neuro-degenerative disease). * Diagnosis of severe eosinophilic asthma * Death of spouse, main informal carer or first-degree family member within the last 3 months * Current oral corticosteroid maintenance treatment Phase 3: Phase 3 is a qualitative study on a sample of couples from Phase 2 therefore the same exclusion criteria will apply as in Phase 2.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adjustment are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Respiratory Medicine, Aberdeen Royal Infirmary
Aberdeen, Grampian, AB25 2ZN, United Kingdom
-
Glasgow Gartnavel General Hospital
Glasgow, G12 0YN, United Kingdom
-
Hull University Teaching Hospitals NHS Trust
Hull, Yorkshire, HU16 5JQ, United Kingdom
-
Judit Varkonyi-Sepp
Southampton, Hampshire, SO166YD, United Kingdom
-
Pinderfields Hospital
Wakefield, Yorkshire, WF1 4DG, United Kingdom
-
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Haptic feedback for improved interoceptive awareness and mental well-being: a comprehensive In-the-Wild study for wellness
- The effect of stress ball use during femoral arterial sheath removal after coronary angiography on pain, anxiety, patient satisfaction, and hemodynamic parameters
- The dynamic mechanism of mindfulness intervention for emotional distress (MIED) based on ecological moment measurement
- Role of self-focused attention in depression
- Project QUIT+: adapting and testing a smoking cessation intervention for transgender and gender expansive individuals
- Interactions between food processing level, nutrition quality, nutrition security and anxiety in israeli adults: influence on dietary intake